Thus, this dual inhibition will enhance the anti-leukemic effect in patients with HR ALL, who showed, as we demonstrated, high expression of CK2, impaired activity of IKZF1 and disruption of the PI3K/AKT/mTOR pathway [33]. This evidence concerns the gene MTOR and acute lymphoblastic leukemia.